6-week Safety and PD Study in Adults With NAFLD

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 27, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

April 27, 2018

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Placebo

0 mg

DRUG

PF-06835919 Low Dose

75 mg once daily

DRUG

PF-06835919 High Dose

300 mg once daily

Trial Locations (9)

23294

National Clinical Research, Inc, Richmond

32720

Avail Clinical Research, LLC, DeLand

32763

Avail Clinical Research, LLC, Orange City

33143

Qps-Mra, Llc, South Miami

33145

Stand-Up MRI of Miami, Miami

37421

WR-ClinSearch LLC, Chattanooga

45219

Sterling Research Group, Ltd., Cincinnati

78229

Clinical Trials of Texas, Inc., San Antonio

90057

National Research Institute, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY